文献速递肿瘤 PET/CT

18F-FAPI-04 PET/CT 预测接受同步放化疗的食管鳞状细胞癌患者的疗效反应

Response Prediction Using 18F-FAPI-04 PET/CT in Patients with Esophageal Squamous Cell Carcinoma Treated with Concurrent Chemoradiotherapy.
PubMed 文献 · J Nucl Med · 2022-10-13

这项前瞻性研究纳入18例局部晚期食管鳞状细胞癌患者,在同步放化疗前进行18F-FAPI-04 PET/CT显像,评估示踪剂摄取参数能否预测短期疗效。结果显示,非缓解者的TBRblood、TBRmuscle和SUVmean显著高于缓解者,多因素分析中TBRblood是短期疗效的独立预后因素,较高的基线TBRblood与较差的放化疗反应相关。

要点

  • 非缓解者的TBRblood、TBRmuscle和SUVmean显著高于缓解者,差异均有统计学意义(P<0.05)。
  • TBRblood、TBRmuscle和SUVmean均可显著预测同步放化疗反应,截断值分别为10.68、10.95和6.88。
  • 多因素分析中TBRblood是短期疗效的独立预后因素(P=0.046)。

核心结论

  • 基线18F-FAPI-04 PET/CT上较高的TBRblood与局部晚期食管鳞状细胞癌患者较差的同步放化疗反应相关,TBRblood可能有助于在同步放化疗前筛选患者。

研究设计与样本

  • 前瞻性研究纳入18例局部晚期食管鳞状细胞癌患者,在同步放化疗前进行18F-FAPI-04 PET/CT扫描。
  • 记录原发肿瘤的SUVmax、SUVmean、SUVpeak、代谢肿瘤体积和总病灶成纤维细胞活化蛋白表达,并测量原发肿瘤SUVmax与正常组织(肌肉和血液)SUVmean的比值,分别记为TBRmuscle和TBRblood。
  • 按RECIST(1.1版)将患者分为缓解者和非缓解者,比较两组间变量。

主要发现

  • 非缓解者的TBRblood、TBRmuscle和SUVmean显著高于缓解者(均P<0.05)。
  • 受试者工作特征曲线分析显示,TBRblood(曲线下面积[AUC]0.883;P=0.008)、TBRmuscle(AUC 0.896;P=0.006)和SUVmean(AUC 0.870;P=0.010)是同步放化疗反应的显著预测因素,截断值分别为10.68、10.95和6.88。
  • TBRblood的敏感度、特异度、阳性预测值、阴性预测值和准确率分别为100.0%、72.7%、66.7%、88.9%和77.8%。
  • TBRmuscle的敏感度、特异度、阳性预测值、阴性预测值和准确率分别为100.0%、72.7%、66.7%、88.9%和77.8%。
  • SUVmean的敏感度、特异度、阳性预测值、阴性预测值和准确率分别为85.7%、81.8%、75.0%、90.0%和83.3%。

关键数值与推荐

  • 单因素logistic回归分析显示,TBRblood(P=0.026)、TBRmuscle(P=0.036)、SUVmean(P=0.045)和肿瘤部位(P=0.032)与短期结局显著相关。
  • 多因素logistic回归分析显示,TBRblood(P=0.046)是短期结局的独立预后因素。

临床怎么用

  • 原文结论认为TBRblood可能有助于在同步放化疗前筛选局部晚期食管鳞状细胞癌患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This prospective study examined whether imaging results obtained using the tracer 18F-AlF-NOTA-fibroblast activation protein inhibitor (FAPI)-04 (denoted as 18F-FAPI-04) in PET/CT can predict the short-term outcome in patients with locally advanced esophageal squamous cell carcinoma (LA-ESCC) treated with concurrent chemoradiotherapy (CCRT). Methods: The 18 enrolled LA-ESCC patients underwent 18F-FAPI-04 PET/CT scanning before CCRT. The SUVmax, SUVmean, SUVpeak, metabolic tumor volume, and total lesion fibroblast activation protein expression of the primary tumor were recorded. Additionally, the SUVmax of the primary tumor and SUVmean of normal tissue (muscle and blood) were measured, and their ratios were denoted as target-to-background ratios (TBRmuscle and TBRblood). Patients were classified as responders or nonresponders according to RECIST (version 1.1), and variables were compared between the 2 groups. Results: The TBRblood, TBRmuscle, and SUVmean were significantly higher in nonresponders than in responders (all P < 0.05). Receiver-operating-characteristic curve analysis identified TBRblood (area under the curve [AUC], 0.883; P = 0.008), TBRmuscle (AUC, 0.896; P = 0.006) and SUVmean (AUC, 0.870; P = 0.010) as significant predictors of the response to CCRT, with cutoffs of 10.68, 10.95, and 6.88, respectively. The sensitivity, specificity, positive predictive value, negative predictive value, and accuracy were also determined for TBRblood (100.0%, 72.7%, 66.7%, 88.9%, and 77.8%, respectively), TBRmuscle (100.0%, 72.7%, 66.7%, 88.9%, and 77.8%, respectively), and SUVmean (85.7%, 81.8%, 75.0%, 90.0%, and 83.3%, respectively). On univariate logistic regression analysis, TBRblood (P = 0.026), TBRmuscle (P = 0.036), SUVmean (P = 0.045), and tumor site (P = 0.032) were significantly correlated with the short-term outcome. On multivariable logistic regression analysis, TBRblood (P = 0.046) was an independent prognostic factor for short-term outcome. Conclusion: A higher baseline TBRblood on 18F-FAPI-04 PET/CT scans was associated with a poor response to CCRT in LA-ESCC patients, and thus, TBRblood may be useful for screening LA-ESCC patients before CCRT treatment.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Hu X, Zhou T, Ren J, et al. Response Prediction Using 18F-FAPI-04 PET/CT in Patients with Esophageal Squamous Cell Carcinoma Treated with Concurrent Chemoradiotherapy. J Nucl Med. 2022. PMID: 36229183. doi:10.2967/jnumed.122.264638

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。